EBR Systems' Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results
Data Presented at Late-Breaking Session at Heart Rhythm Society 2023: Paves Way for Premarket Approval Application for Federal Drug...
top of page
A L T I T U D E
Life Science Ventures
Companies in the News
- Apr 27, 2023
Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement
Multi-year collaboration will facilitate the co-development of optimized therapeutics that bind to challenging targets in ways...
- Apr 13, 2023
Sana Biotechnology Announces Preclinical Data Published in Nature Communications
Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic...
- Mar 10, 2023
Ring Therapeutics Raises $86.5M in Series C Funding to Create Next Generation Programmable Medicines
Ring raised a total of $86.5 million from new and returning investors, validating its unique approach to creating next-generation...
- Feb 16, 2023
Aera Therapeutics Launches with $193 M for the Next Generation of Transformative Genetic Medicines
Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range...
- Jan 9, 2023
Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms
RNA Gene Writing™ platform demonstrates clinically relevant levels of in vivo rewriting in the genome of liver cells of non-human...
- Jan 6, 2023
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin
Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated...
- Dec 21, 2022
DNA Writing Goes Enzymatic, Encourages Pursuit of Bold Visions
The 1950s are widely recognized as one of the most important decades in biology. This is, in large part, due to the discovery of the...
- Dec 19, 2022
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
Phase 1b study designed to determine the safety and dose of NUV-868 in combination with olaparib or enzalutamide for the treatment of...
bottom of page